Literature DB >> 16431124

Clinical trials design and treatment tailoring: general principles applied to breast cancer research.

P Therasse1, S Carbonnelle, J Bogaerts.   

Abstract

Nowadays tailored therapy tends to replace standard cancer treatment approaches. Tailoring treatment is possible thanks to clinical trials results that identified subgroups of patients benefiting most from some treatments. Treatment can be tailored on the basis of specific clinical characteristics of the population or on the basis of predictive or prognostic markers. Finally treatment can be tailored for specific molecular targets. This evolution in cancer treatment has triggered the development of innovative trial designs to validate these new hypotheses. The real challenge of the next coming years resides in recruiting large number of patients from specific subgroups to validate tailored therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16431124     DOI: 10.1016/j.critrevonc.2005.11.003

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  4 in total

1.  Randomized clinical trials with biomarkers: design issues.

Authors:  Boris Freidlin; Lisa M McShane; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2010-01-14       Impact factor: 13.506

Review 2.  Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Ruwanthi Kolamunnage-Dona; Andrea L Jorgensen
Journal:  J Pers Med       Date:  2017-01-25

3.  Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.

Authors:  Xian Zhou; Suyu Liu; Edward S Kim; Roy S Herbst; J Jack Lee
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

4.  Time-dependent endpoints as predictors of overall survival in multiple myeloma.

Authors:  Jorge Félix; Filipa Aragão; João M Almeida; Frederico J Calado; Diana Ferreira; António B S Parreira; Ricardo Rodrigues; João F R Rijo
Journal:  BMC Cancer       Date:  2013-03-16       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.